Top 100 US Patents in Preparations
section a - human necessities > medical or veterinary science; hygiene > preparations for medical, dental, or toilet purposes
Sorted by IPQ® Score, an objective measure of patent quality. View scores and methodology at PatentRatings.com. You can also view all by publication date instead.
US4588585 (A), filed
Sep 28, 1984
, published
May 13, 1986
- CETUS CORP
Muteins of biologically active proteins such as IFN- beta and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect...
US7128908 (B2), filed
Jul 12, 2005
, published
Oct 31, 2006
- UNIV NEW YORK
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
US7332573 (B2), filed
Jun 27, 2002
, published
Feb 19, 2008
- GENENTECH INC
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptid...
US4500523 (A), filed
Apr 09, 1984
, published
Feb 19, 1985
- CORNELL RES FOUNDATION INC
This invention relates to the use of aromatase inhibitors to suppress premature labor in mammals by administering an aromatase inhibitor preferably 4-hydroxy-4-androstene-3,17-dione or 4-acetoxy-4-androstene-3,17-dione to a pregnant mammal.
US6720166 (B2), filed
Jun 05, 1995
, published
Apr 13, 2004
- ABBOTT LAB
Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to...
US7022822 (B1), filed
Jan 15, 2002
, published
Apr 04, 2006
- INST MASSONE S A
Purification process of humanPurification process of human urinary gonadotropins of high biological activity and chemical purity absolutely free of foreign contaminating materials derived from the use of biological reagents or chromatography dyes, from crude...
US4775624 (A), filed
Feb 08, 1985
, published
Oct 04, 1988
- LILLY CO ELI
The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive...
US4724232 (A), filed
Sep 17, 1985
, published
Feb 09, 1988
- BURROUGHS WELLCOME CO
Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the...
US7214376 (B2), filed
Dec 07, 2001
, published
May 08, 2007
- CENTOCOR INC
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
US7335358 (B2), filed
Dec 04, 2006
, published
Feb 26, 2008
- UNIV NEW YORK
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
US7138118 (B2), filed
Dec 08, 2005
, published
Nov 21, 2006
- UNIV NEW YORK
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
US6417429 (B1), filed
Nov 25, 1998
, published
Jul 09, 2002
- SCRIPPS RESEARCH INST
The present invention relates to expression and assembly of foreign multimeric proteins-e.g., antibodies-in plants, as well as to transgenic plants that express such proteins. In one of several preferred embodiments, the generation and assembly of functional...
US5915378 (A), filed
Oct 27, 1995
, published
Jun 29, 1999
- ARADIGM CORP
Devices, packaging and methodology for efficiently and repeatably creating aerosolized bursts of an insulin containing formulation are disclosed. Devices are hand-held, self-contained units which are automatically actuated at the same release point in a...
US7094230 (B2), filed
Dec 16, 2003
, published
Aug 22, 2006
- MEDTRONIC VASCULAR INC
An implantable reservoir device ( 400 ) including an enclosed membrane ( 408 ) on an expandable frame ( 402 ) that defines a reservoir ( 410 ) and includes a porous region ( 418 ). The reservoir device ( 400 ) may be deployed and expanded within a blood...
US6702705 (B1), filed
Feb 22, 1995
, published
Mar 09, 2004
- IGEN INT INC
Catalytic antibodies are disclosed. The catalytic antibodies are specific for prodrug compounds. The catalytic antibodies enhance cleavage of an active drug moiety from a prodrug residue, thereby activating the drug.
US7361732 (B2), filed
May 08, 2002
, published
Apr 22, 2008
- GENENTECH INC
The present invention is directed to novel polypeptide and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptide...
US4374829 (A), filed
Feb 17, 1981
, published
Feb 22, 1983
- MERCK CO INC
The invention relates to new carboxyalkyl dipeptide derivatives and related compounds which are useful as antihypertensives.
US5246692 (A), filed
Aug 22, 1991
, published
Sep 21, 1993
- US HEALTH
New polysubstituted diethylenetriaminepentaacetic acid chelates and protein conjugates of the same are described together with the methods of preparing such compounds. A method of delivering radiolabelled compound of the present invention to a target site...
US5352517 (A), filed
Jan 18, 1994
, published
Oct 04, 1994
- ENSCI INC
Processes for coating substrates, in particular substrates including shielded surfaces, with iron oxide-containing coatings are disclosed. Such processes comprise contacting a substrate with an iron oxide precursor, preferably maintaining the precursor coated...
US4259477 (A), filed
Jun 04, 1979
, published
Mar 31, 1981
- MERCK CO INC
Cellulase in xanthan gum can be completely destroyed by treating xanthan gum beer with about 0.08 to 0.1% alkali metal hypochlorite followed by heat treatment.
US4627977 (A), filed
Sep 13, 1985
, published
Dec 09, 1986
- COLGATE PALMOLIVE CO
An oral composition such as a toothpaste (including gel or cream), mouthwash, lozenge, chewing gum or tooth powder containing a calculus-inhibiting amount of a linear molecularly dehydrated polyphosphate salt and, to inhibit enzymatic hydrolysis of said...
US4477469 (A), filed
Jun 26, 1981
, published
Oct 16, 1984
- HERSCHLER R J
Preparations containing methylsulfonylmethane (MSM) for administration to the skin, nails, other tissue and/or body fluids of a human or other animal subject are disclosed. Such compositions soften skin, strengthen nails and provide other benefits when applied...
US6967201 (B1), filed
May 06, 2002
, published
Nov 22, 2005
- LILLY CO ELI
The present invention provides serotonergic benzofurylpiperazines of Formula I: where: A is a piperazine of formula: and R, RSUP1/SUP, RSUP2/SUP, RSUP3/SUP, RSUP4/SUP, RSUP5/SUP, RSUP5'/SUP, RSUP6/SUP, RSUP6'/SUP, RSUP7/SUP, RSUP7'/SUP, RSUP8/SUP, and...
US5665713 (A), filed
Apr 12, 1995
, published
Sep 09, 1997
- PROCTER GAMBLE
This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition is also effective against viruses. The composition contains N-phosphonoglycine derivatives...
US5919665 (A), filed
Mar 16, 1995
, published
Jul 06, 1999
- OPHIDIAN PHARM INC
The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of...
US6770673 (B1), filed
Feb 01, 1999
, published
Aug 03, 2004
- PARACURE INC
Compositions and kits containing a first chemotherapeutic agent that includes arglabin or a derivative thereof and a second chemotherapeutic agent are described. The compositions and kits are effective for treating cancer in a human patient. Methods for...
US6165497 (A), filed
Mar 01, 1991
, published
Dec 26, 2000
- ALZA CORP
Rate controlled transdermal nicotine delivery systems are disclosed which utilize an in-line adhesive to maintain the systems on the skin. The initial equilibrated concentration of nicotine in the nicotine reservoir and the adhesive is below saturation,...
US6060056 (A), filed
Sep 08, 1993
, published
May 09, 2000
- JOLLA PHARMA
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are...
US5837500 (A), filed
Apr 03, 1995
, published
Nov 17, 1998
- DYAX CORP
In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a...
US6780613 (B1), filed
Jun 07, 1995
, published
Aug 24, 2004
- GENENTECH INC
The invention provides methods for the systematic analysis of the structure and function of polypeptides by identifying active domains which influence the activity of the polypeptide with a target substance. Such active domains are determined by substituting...
US7223396 (B2), filed
Dec 12, 2002
, published
May 29, 2007
- UNIV NEW YORK
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
US6090914 (A), filed
Apr 15, 1994
, published
Jul 18, 2000
- SQUIBB BRISTOL MYERS CO
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid...
US7135179 (B2), filed
Jul 13, 2005
, published
Nov 14, 2006
- UNIV NEW YORK
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
US7169386 (B1), filed
Jan 10, 2002
, published
Jan 30, 2007
- CENTOCOR INC
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
US7312207 (B2), filed
May 19, 2004
, published
Dec 25, 2007
- TARO PHARMACEUTICALS NORTH AME
Disclosed is a novel mometasone furoate cream formulation for topical administration in a oleaginous base containing propylene glycol. This cream is a cosmetically elegant preparation of mometasone that is both stable and bioeffective.
US5902610 (A), filed
Nov 03, 1995
, published
May 11, 1999
- BIONUMERIK PHARMACEUTICALS INC
This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis...
US5733950 (A), filed
Sep 25, 1995
, published
Mar 31, 1998
- ATRIX LAB INC
A biodegradable polymer is provided for use in providing syringeable, in-situ forming, solid biodegradable implants for animals. The polymer is placed into the animal in liquid form and cures to form the implant in-situ. A thermoplastic system to form said...
US7291704 (B2), filed
Jun 27, 2002
, published
Nov 06, 2007
- GENENTECH INC
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptid...
US7014841 (B2), filed
Mar 31, 2004
, published
Mar 21, 2006
- ALEXZA PHARMACEUTICALS INC
The present invention relates to the delivery of antiemetics through an inhalation route. Specifically, it relates to aerosols containing antiemetics that are used in inhalation therapy. In a method aspect of the present invention, an antiemetic is delivered...
US7404955 (B2), filed
Aug 02, 2005
, published
Jul 29, 2008
- UNIV NEW YORK
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
US5919452 (A), filed
Feb 04, 1994
, published
Jul 06, 1999
- UNIV NEW YORK
Treatment of tumor necrosis factor, TNF, mediated pathologies is provided by administering anti-TNF compounds, such as anti-TNF antibodies and anti-TNF peptides, which compounds are specific for tumor necrosis factor- alpha (TNF alpha ) or tumor necrosis...
US7223838 (B2), filed
May 03, 2002
, published
May 29, 2007
- GENENTECH INC
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptid...
US5290589 (A), filed
Aug 12, 1991
, published
Mar 01, 1994
- ENSCI INC
Processes for coating substrates, in particular substrates including shielded surfaces, with iron oxide-containing coatings are disclosed. Such processes comprise contacting a substrate with an iron oxide precursor, preferably maintaining the precursor coated...
US6889072 (B2), filed
Jul 05, 2001
, published
May 03, 2005
The present invention is a method and apparatus for providing preferential enhancement of an artery of interest relative to adjacent veins and background tissue. The method and apparatus adapts the timing of a maximum or substantially elevated rate of infusion...
US5460967 (A), filed
May 27, 1994
, published
Oct 24, 1995
- RANPAK CORP
The invention includes a method that produces a low cost aqueous solution of solubilized collagen by the steps of: (a) providing an aqueous ground slurry of insoluble collagen and adjusting the pH of said slurry to obtain activity for a proteolytic enzyme...
US5460967 (B1), filed
May 27, 1994
, published
Mar 10, 1998
- RANPAK CORP CONCORD
US6458527 (B1), filed
Jun 28, 1993
, published
Oct 01, 2002
- CHIRON CORP
Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to...
US7053185 (B1), filed
Aug 15, 2000
, published
May 30, 2006
- HAMLET PHARMA AB
A method for producing an oligomeric form of alpha-lactalbumin which is in the molten globule-like state is described. The method suitably comprises exposing a source of alpha-lactalbumin in which the alpha-lactalbumin is preferably in the molten globule-like...
US7094282 (B2), filed
Apr 16, 2003
, published
Aug 22, 2006
- CALCITEC INC
A calcium phosphate cement suitable for use in dental and bone prosthesis is disclosed, which include calcium phosphate particles having a diameter of 0.05 to 100 microns, wherein said calcium phosphate particles on their surfaces have whiskers or fine...
US6833132 (B1), filed
May 31, 1995
, published
Dec 21, 2004
- US HEALTH
Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used sucessfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various...
US7393949 (B1), filed
May 17, 1995
, published
Jul 01, 2008
- NOVARTIS VACCINES DIAGNOSTIC
Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to...
US5760068 (A), filed
Sep 06, 1996
, published
Jun 02, 1998
- SEARLE CO
PCT No. PCT/US94/12720 Sec. 371 Date Sep. 6, 1996 Sec. 102(e) Date Sep. 6, 1996 PCT Filed Nov. 14, 1994 PCT Pub. No. WO95/15316 PCT Pub. Date Jun. 8, 1995A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and...
US7018620 (B2), filed
Feb 09, 2004
, published
Mar 28, 2006
- ALEXZA PHARMACEUTICALS INC
The present invention relates to the delivery of atenolol, pindolol, esmolol, propranolol, or metoprolol through an inhalation route. Specifically, it relates to aerosols containing atenolol, pindolol, esmolol, propranolol, or metoprolol that are used in...
US7094392 (B2), filed
Dec 30, 2003
, published
Aug 22, 2006
- ALEXZA PHARMACEUTICALS INC
The present invention relates to the delivery of antihistamines through an inhalation route. Specifically, it relates to aerosols containing antihistamines that are used in inhalation therapy. In a method aspect of the present invention, an antihistamine is...
US4386085 (A), filed
Jan 08, 1982
, published
May 31, 1983
- ROUSSEL UCLAF
Novel 19-nor steroids and 19-nor-D-homo-steroids of the formula IMAGE I' wherein R1 is an organic radical of 1 to 18 carbon atoms containing at least one atom selected from the group consisting of nitrogen, phosphorous and silicon with the atom immediately...
US4673574 (A), filed
Jul 05, 1983
, published
Jun 16, 1987
- ANDERSON PORTER W
An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having a reducing end and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also...
US5650096 (A), filed
Dec 09, 1994
, published
Jul 22, 1997
- GENZYME CORP
Novel cationic amphiphiles are provided that facilitate transport of biologically active molecules into cells. Typically, the amphiphiles contain lipophilic groups derived from steroids or from mono or dialkylamines, and two cationic groups, protonatable at...
US6025377 (A), filed
Aug 21, 1998
, published
Feb 15, 2000
- PROCTER GAMBLE
A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals that comprises a material is disclosed. The particular material used is a 1H-1,2,4-triazole derivative. These compounds can also be used to treat viral infections.
US5003080 (A), filed
Feb 01, 1989
, published
Mar 26, 1991
- WARNER LAMBERT CO
US6759062 (B2), filed
Jan 05, 2001
, published
Jul 06, 2004
- BIOSELECT INNOVATIONS INC
An improved medicinal composition includes an effective amount of an antihistamine pharmaceutical and an effective amount of a nutraceutical in a pharmaceutically acceptable base. At least one of the pharmaceutical and the nutraceutical treats a condition...
US5783421 (A), filed
Jun 06, 1995
, published
Jul 21, 1998
- BIO TECHNOLOGY GENERAL CORP
A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism...
US4558120 (A), filed
Dec 27, 1983
, published
Dec 10, 1985
- DOW CHEMICAL CO
Dense star polymers having terminal group densities greater than conventional star polymers exhibit greater and more uniform reactivity than their corresponding conventional star polymers. For example, a third generation, amine-terminated polyamidoamine dense...
US7371257 (B2), filed
Nov 23, 2004
, published
May 13, 2008
- BOSTON SCIENT SCIMED INC
The invention features a catheter assembly and methods for delivering a hydrogel-lined stent to a body lumen, and methods for lining a stent with a hydrogel. The assembly includes a catheter which has a balloon at least a portion of which is coated with a...
US7070761 (B2), filed
Dec 12, 2003
, published
Jul 04, 2006
- ALEXZA PHARMACEUTICALS INC
The present invention relates to the delivery of nonsteroidal antiinflammatory drugs (NSAIDs) through an inhalation route. Specifically, it relates to aerosols containing NSAIDs that are used in inhalation therapy. In a method aspect of the present invention,...
US5750657 (A), filed
Oct 18, 1993
, published
May 12, 1998
- SQUIBB BRISTOL MYERS CO
The subject invention relates to methods and compositions using nondynamic fibrin monomer which is selectively converted to a fibrin polymer which serves as the fibrin sealant.
US7005121 (B2), filed
Dec 12, 2003
, published
Feb 28, 2006
- ALEXZA PHARMACEUTICALS INC
The present invention relates to the delivery of a migraine headache drug through an inhalation route. Specifically, it relates to aerosols containing a migraine headache drug that are used in inhalation therapy. In a method aspect of the present invention, a...
US7425330 (B2), filed
Oct 16, 2006
, published
Sep 16, 2008
- UNIV NEW YORK
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
US5700778 (A), filed
Jun 02, 1995
, published
Dec 23, 1997
- SALK INST FOR BIOLOGICAL STUDI
Substantially pure conotoxins are provided which inhibit synaptic transmissions at the neuromuscular junctions and which are useful both in vivo and in assays because they specifically target particular receptors, such as the acetylcholine receptor, and ion...
US4792525 (A), filed
Jun 17, 1985
, published
Dec 20, 1988
- JOLLA CANCER RES FOUND
The peptide X-Arg-Gly-Asp-R-Y wherein X is H or at least one amino acid and Y is OH or at least one amino acid, and R is an amino acid selected from Thr or Cys, or other amino acid, having the same cell-attachent activity as fibronectin and the peptide...
US7135166 (B2), filed
Apr 19, 2002
, published
Nov 14, 2006
- WELLA AG
The hair styling stick contains from 30 to 55 percent by weight of one or more polyethylene glycols with a molecular weight of from 2500 to 5000 g/mol; and from 40 to 70 percent by weight of at least one other polyethylene glycol with a molecular weight of...
US7150870 (B2), filed
Sep 04, 2003
, published
Dec 19, 2006
- COMBI CO
The invention prevents or treats a tumor, inhibiting tumor growth and malignant progression by providing an antitumor agent containing a treated SOD as the active ingredient, especially a melon SOD coated with gliadin. The invention also applies to a method of...
US7166284 (B2), filed
Feb 21, 2003
, published
Jan 23, 2007
- CENTOCOR INC
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
USRE39146 (E1), filed
Jul 15, 1998
, published
Jun 27, 2006
- BRACCO INT BV
One can impart outstanding resistance against collapse under pressure to gas-filled microvesicle used as contrast agents in ultrasonic echography by using as fillers gases whose solubility in water, expressed in liter of gas by liter of water under standard...
US4278689 (A), filed
Aug 02, 1979
, published
Jul 14, 1981
- AMERICAN CYANAMID CO
This disclosure describes symmetrical 1,4-bis(substituted-amino)-5,8-dihydroxyanthraquinones useful as chelating agents and for inhibiting the growth of transplanted mouse tumors.
US7028686 (B2), filed
Nov 04, 2003
, published
Apr 18, 2006
- ARADIGM CORP
Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient...
US6846676 (B2), filed
Jun 08, 1999
, published
Jan 25, 2005
- TRANSKARYOTIC THERAPIES INC
The invention provides primary and secondary cells that are transfected with a nucleic acid molecule that encodes erythropoietin, clonal or heterogenous strains of such cells, and methods of producing these cell strains.
US6861212 (B1), filed
May 15, 1995
, published
Mar 01, 2005
- CHIRON CORP
A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected...
US7144900 (B2), filed
Sep 10, 2004
, published
Dec 05, 2006
- TAKEDA PHARMACEUTICAL
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for...
US6177475 (B1), filed
May 12, 1997
, published
Jan 23, 2001
- BILLINGS PHARMACEUTICALS INC
The invention provides methods of treating inflammatory diseases and conditions by administering an effective amount of an integrin modulating agent, as further defined and specified herein, to an animal suffering from one of the diseases or conditions. The...
US6939884 (B2), filed
Dec 03, 2002
, published
Sep 06, 2005
- NOVACTYL INC
Compositions are provided, which comprise at least one nucleoside analogue inhibitor, pharmaceutically acceptable salts, solvates, or prodrugs thereof and fusaric acid, derivatives, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions...
US4567043 (A), filed
Jun 15, 1983
, published
Jan 28, 1986
- AMERICAN HOME PROD
An efficacious parenterally administered modified live Canine Corona virus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent Canine Corona virus is produced. A method for...
US4603112 (A), filed
Dec 08, 1982
, published
Jul 29, 1986
- HEALTH RESEARCH INC
What are disclosed are methods for modifying the genome of vaccinia virus to produce vaccinia mutants, particularly by the introduction into the vaccinia genome of exogenous DNA; modified vaccinia prepared by such methods; certain DNA sequences and unmodified...
US4296130 (A), filed
Aug 30, 1979
, published
Oct 20, 1981
- HERSCHLER R J
Preparations containing methylsulfonylmethane (MSM) for administration to the skin, nails, other tissue and/or body fluids of a human or other animal subject are disclosed. Such compositions soften skin, strengthen nails and provide other benefits when applied...
US7008616 (B2), filed
Apr 01, 2004
, published
Mar 07, 2006
- ALEXZA PHARMACEUTICALS INC
The present invention relates to the delivery of stimulants through an inhalation route. Specifically, it relates to aerosols containing stimulants that are used in inhalation therapy. In a method aspect of the present invention, a stimulant is delivered to a...
US7087216 (B2), filed
Jan 27, 2004
, published
Aug 08, 2006
- ZAFFARONI ALEJANDRO C
The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a method aspect of the present invention, a sedative-hyp...
US7115250 (B2), filed
Dec 30, 2003
, published
Oct 03, 2006
- ALEXZA PHARMACEUTICALS INC
The present invention relates to the delivery of erectile dysfunction drugs through an inhalation route. Specifically, it relates to aerosols containing erectile dysfunction drugs that are used in inhalation therapy. In a method aspect of the present...
US5948821 (A), filed
Jan 11, 1996
, published
Sep 07, 1999
- DAVIDSON JOHN B
The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and antiinflammation effects. In general, Ajoene may be used to...
US6031093 (A), filed
Apr 06, 1995
, published
Feb 29, 2000
- SMITHKLINE BEECHAM PLC
A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts...
US6031093 (C1), filed
Apr 06, 1995
, published
Oct 16, 2001
- SMITHKLINE BEECHAM PLC
US6451314 (B1), filed
Jun 23, 2000
, published
Sep 17, 2002
- ANERGEN INC
The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.
US4568547 (A), filed
Feb 28, 1984
, published
Feb 04, 1986
- HERSCHLER R J
Methylsulfonylmethane (MSM) is useful as a tableting and granulating aid for pharmaceutically active agents, especially those which are unstable in the presence of moisture, mixtures therewith being or formable into free-flowing powders or granules which are...
US6835823 (B2), filed
Jan 08, 2001
, published
Dec 28, 2004
- UNIV NEW YORK
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...
US7351816 (B2), filed
Oct 19, 2004
, published
Apr 01, 2008
- GENENTECH INC
The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic...
US4376769 (A), filed
Jun 19, 1981
, published
Mar 15, 1983
- SCHERING CORP
Disclosed herein are novel tetrahydro imidazo thiazoles, tetrahydro imidazo thiazines, hexahydro imidazo thiazepines and hexahydro imidazo thiazocines, intermediates for the preparation thereof, methods of using the compounds as anti-inflammatory agents and...
US6388094 (B1), filed
Nov 01, 1999
, published
May 14, 2002
- SEARLE CO
A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide from a chiral alpha amino aldehyde.
US6017536 (A), filed
Dec 20, 1994
, published
Jan 25, 2000
- TRIMERIS INC
The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a simian immunodeficiency virus (SIV) protein. These regions were identified through...
US6919308 (B2), filed
Dec 17, 2002
, published
Jul 19, 2005
- STRYKER CORP
Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors...
US7241571 (B2), filed
Dec 19, 2003
, published
Jul 10, 2007
- UNIV CALIFORNIA
5-LO is expressed in the monocyte/macrophages (mono/mac) and foam cells of atherosclerotic lesions and is differentially expressed in CAST and CON6 mice relative to B6 mice. Mice heterozygous for a null mutation of 5-LO, when placed on an LDLR-/- background,...
US5426031 (A), filed
May 25, 1993
, published
Jun 20, 1995
- BAXTER DIAGNOSTICS INC
The Prothrombin Time (PT) is used as a screening test for blood coagulation factor deficiencies and for monitoring oral anti-coagulant therapy using coumadin. Thromboplastin reagents activate the extrinsic pathway of coagulation and are the basis for the...
US6951955 (B2), filed
Sep 18, 2003
, published
Oct 04, 2005
- WYETH CORP
The invention is a process for the preparation of compounds of the Formula I: where RSUB1/SUB, RSUB2/SUB, RSUB3/SUB, RSUB4 /SUBand RSUB5 /SUBare defined in the specification, which are intermediates useful for the preparation of tubulin inhibitors which are...
